



To News Editor
For Immediate Release

14 July 2008

M. D. Anderson Announces Collaboration with The Chinese University of Hong Kong
East-West Partnership to Advance Translational Cancer Research, Education and Patient Care

The University of Texas M. D. Anderson Cancer Center today signed a sister institution agreement with the Sir Y.K. Pao Centre for Cancer and Hong Kong Cancer Institute at The Chinese University of Hong Kong (CUHK), formalizing existing collaborations between the two cancer centers based on their shared missions of scientific discovery, patient therapies, education and prevention.

The institutions have identified nasopharyngeal carcinoma, hepatocellular carcinoma and glioma as initial research areas of focus. Additionally, the collaboration aims to establish a Clinical Trial Network among China, East Asia, and M. D. Anderson, and educational exchange programs for post-graduate students, clinical fellows and oncology nurses with onsite training opportunities at CUHK.

M. D. Anderson's vice president of Global Academic Programs, Karen K. Fields, M.D., joined Anthony T.C. Chan, M.D., director of the Cancer Center at CUHK and professor in the Department of Clinical Oncology at the signing ceremony at Prince of Wales Hospital in Shatin, the New Territories. The event culminated a day-long symposium featuring presentations from faculty at both institutions on personalized cancer medicine, and nasopharyngeal, lung and brain cancers, among others.

Since its opening in 1994, the Cancer Center at CUHK has established a reputation as a leader in cancer care, research and education in southern China and the eastern Asian regions and is noted for research and treatment of Asia-prevalent cancers, including cancers of the nasopharynx, liver, lung and gastrointestinal systems.

“The Chinese University of Hong Kong has renowned clinical and academic research programs and remarkable therapeutic expertise,” said John Mendelsohn, M.D., president of M. D. Anderson Cancer Center. “The new partnership will create and support more opportunities for innovative cancer research collaborations to ultimately reduce the incidence of cancer and suffering among patients globally.”

Cancer is the number one cause of death in China. In 2004, approximately 1,892,000 people died from cancer¹ and the number of new cases is increasing at a rapid rate, especially in densely populated Southern provinces. Compared with other countries, China and Hong Kong have the highest incidence of hepatocellular carcinoma (HCC) and nasopharyngeal cancer (NPC) in the world, respectively. The incidence of other cancers prevalent in China, such as lung, gastric and esophageal cancers, also rank among the top 10 in the world.

¹ World Health Organization Global Infobase

“The alarming rise in cancer rates in rural and urban provinces of China underscores the great need for collaboration among the world’s leading cancer programs,” said Professor Chan. “Our sister agreement with M. D. Anderson will enable us to expand our existing academic and educational partnership and increase the active sharing of knowledge and clinical experiences to better understand and treat the disease.”

The sister agreement builds on 5 years of collaborative investigations among researchers and clinicians at both institutions in the areas of nasopharyngeal cancers; viruses in patients with virus-associated and related cancers; and physician exchanges and educational activities including annual educational seminars (Hematology and Medical Oncology) and clinical fellowship programs with the departments of Radiation Oncology and Neuro-oncology.

The signing ceremony and workshop were attended by Dr. Fields and M. D. Anderson faculty members including W. K. Alfred Yung, M.D., professor and chair of the Department of Neuro-Oncology; Gordon B. Mills, M.D., Ph.D., professor and chair of the Department of Systems Biology; Li Mao, M.D., professor, Department of Thoracic/Head and Neck Medical Oncology; and T.J. Liu, Ph.D., project manager for Global Academic Programs. Participants representing The Chinese University of Hong Kong included Professor Anthony T.C.Chan; Tai Fai Fok, Dean, Faculty of Medicine; Ho Keung Ng, Associate Dean (Education); Y.M. Dennis Lo, Associate Dean (Research); Wai Sang Poon, chief of the Division of Neurosurgery; Andrew van Hasselt, chairman of the Department of Surgery; Allen K.C. Chan, assistant professor, Department of Chemical Pathology; Tony S.K. Mok, professor, Department of Clinical Oncology; Nathalie Wong, professor, Department of Anatomical and Cellular Pathology; and Vivian W.Y. Lui, assistant professor, Department of Clinical Oncology.

To date, M. D. Anderson has established sister institution relationships with 18 premier academic and clinical cancer centers around the world, and partnered with the Department of State on a similar breast cancer initiatives in the Middle East and the South Americas. Experts from all international sister and breast cancer partner institutions gathered in Houston in June for M. D. Anderson's annual Global Academic Program Conference.

About M. D. Anderson

The University of Texas M. D. Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. M. D. Anderson is one of only 39 Comprehensive Cancer Centers designated by the National Cancer Institute. For five of the past eight years, M. D. Anderson has ranked No. 1 in cancer care in “America's Best Hospitals,” a survey published annually in U.S. News and World Report.

About The Chinese University of Hong Kong

The Hong Kong Cancer Institute was established in 1990 to coordinate, promote and organize activities relating to the prevention and treatment of cancer; to promote and provide training in cancer research; to educate the public on methods of prevention and the early treatment of cancer; to improve the welfare of cancer patients; and to organize seminars, workshops and conferences for advancing its objectives. Most of the institute's activities are conducted in the Sir Y.K. Pao Centre for Cancer located at the Prince of Wales Hospital. Opened in 1994, the centre provides clinical and counseling services through a paediatric oncology ward, out-patient and day-patient facilities for adults, and a comprehensive range of diagnostic facilities. Comprehensive Cancer Trials Unit (CCTU) is the first centre in Hong Kong, approved by the National Cancer Institute (NCI) in the United States in 2002, to conduct new NCI drug clinical studies, with investigators in CUHK acting as Principal Investigators. With close partnership with industry, government and charitable organizations, CCTU has initiated and undertaken clinical trials in a wide range of cancers.



致新聞編輯
請即發放

中大宣佈與美國德薩斯大學安德遜癌症中心建立策略性合作 東西夥伴關係促進癌症的研究、教育及治療

香港中文大學（中大）香港癌症研究所及包玉剛爵士癌症中心今天（7月14日）與美國德薩斯大學安德遜癌症中心簽訂姊妹機構協議，正式在現有的合作基礎上，進一步加強協作，以實踐雙方在科研、病人治療、教育及防治各方面的共同使命。

雙方已確立鼻咽癌、肝癌及神經膠質瘤為首期重點研究。另外，協作將有助建立中國、東亞地區及安德遜癌症中心的臨床試驗聯繫網絡，促進雙方醫療研究生及醫護人員的交流，並提供在中大接受培訓的機會。

是次簽訂儀式由安德遜癌症中心全球學術項目副主席 Dr. Karen K Fields 及中大腫瘤學講座教授暨香港癌症研究所及包玉剛爵士癌症中心總監陳德章教授主持，並邀得多位安德遜癌症中心的學者出席，包括神經腫瘤學系部門主管及神經學教授翁維鈞教授、系統生物部門主管及系統生物教授 Professor Gordon Mills、胸椎頭頸教授 Professor Li Mao 及全球學術項目經理 Mr. TJ Liu。出席的中大學者則包括中大醫學院院長霍泰輝教授、副院長（教育）吳浩強教授、副院長（研究）盧煜明教授、外科講座教授潘偉生教授、外科學系系主任尹懷信教授、化學病理學系助理教授陳君賜教授、病理解剖及細胞學系王昭春教授、腫瘤學系莫樹錦教授及腫瘤學系助理教授呂偉欣教授。簽訂儀式後隨即舉行研討會，多位專家就鼻咽癌、肺癌及腦癌等疾病交流最新的醫療知識。

自 1994 年成立以來，中大包玉剛爵士癌症中心在華南及東亞地區的癌症治療、研究及教育領域上一直處於領導地位，尤其以關於鼻咽癌、肝癌、肺癌及腸胃癌等亞洲常見癌症的研究及治療成效見稱。

安德遜癌症中心主席 John Mendelsohn 表示：「中大的臨床及學術研究項目享負盛名，且醫術卓越。我們與中大簽訂為姊妹機構後，將進一步促進雙方合作，以創新的方法研究癌症，希望減低全球的癌症發病率及癌症病人所承受的痛苦。」

癌症是中國的頭號殺手。在 2005 年，中國約有 1,892,000 人死於癌症，有關病例更不斷飆升，尤其在人口密集的南部省份更為顯著。相對於其他國家，肝癌和鼻咽癌的病發率在中國內地和香港均排行首位。而肺癌、胃癌及食道癌等在中國普遍的癌症更被列為全球十大癌症殺手。

「基於近年在中國城市及農村的癌症病例不斷上升，世界各地的癌症研究人員實在有必要加強合作，共同為癌症尋找治療方案，為病人謀福祉。」陳德章教授更指出：「與安德遜癌症中心簽訂姊妹機構協議，將拓闊中大現有的學術及教育夥伴，增進交流知識和臨床經驗，有助增加對癌症的認識及治療成效。」

姊妹機構協議有效期為五年，雙方的研究及醫護人員將共同就鼻咽癌及病毒相關的癌症尋求最新的醫療方案。另外，雙方亦會為內科醫生籌辦交流計劃及教育活動，包括每年一次的醫學研討會（血液及腫瘤內科），以及為放射科及腦科腫瘤部門開設培訓計劃等。

安德遜癌症中心迄今已與全球 18 所重要的學術及臨床癌症機構建立姊妹關係，並與美國國務院合作，在中東及南美建立以乳癌為主要研究項目的夥伴關係。來自世界各地姊妹機構的專家及乳癌夥伴機構剛於本年六月齊集美國安德遜癌症中心，參加全球學術會議。

有關美國德薩斯大學安德遜癌症中心

美國德薩斯大學安德遜癌症中心是全球備受重視的癌症中心之一，著重癌症病人的關懷、學術研究、教育及防治。中心也是國際癌症中心 39 個綜合癌症中心之一。過去八年，中心曾五度被美國新聞及世界報刊的年度調查選為「最佳醫院」之冠。

有關中大香港癌症研究所及包玉剛爵士癌症中心

香港癌症研究所於 1990 年成立，主要組織及推廣有關預防及治療癌病的活動，透過研討會、工作坊及會議，加強教育公眾對預防癌症及早期癌症治療方法的知識，並致力為癌症病人謀福祉。研究所亦提供癌症研究的訓練。該所的主要活動均在沙田威爾斯親王醫院的包玉剛爵士癌症中心內舉行。

包玉剛爵士癌症中心於 1994 年成立，中心透過兒科腫瘤病房、成人門診及日診各類的診斷設備，提供臨床及輔導服務。另外，中大綜合癌症研究中心（CCTU）在 2002 年獲得美國國家癌症研究所批准，在中大研究員的領導下進行新藥研究，透過藥廠、政府及慈善組織的緊密合作，中大綜合癌症研究中心開展了多種癌病的臨床試驗。

2008 年 7 月 14 日